Categories
- PROTAC Linker
- Protein Control Ligand
- Pathway Inhibitors
- Function Modulators
- Activators
- G Protein-Coupled Receptor Ligands
- Nuclear Receptor Ligands
- GDNF Receptors
- TNF Receptors
- Transcription Factors
- Chemokines
- Cytokine Receptors
- Biomarkers and Buffer Solutions
- Molecular Probes
- Stem Cell Research
- Alzheimer's Disease
- Apoptosis
- Cancer Research
- Epigenetics
- Metabolites
- PET/SPECT Imaging Precursors
- Customized Screening Library
- Ultra Pure Pharmacological Standard
- Tissue Microarray (TMA)
- Proteins and Antibodies
- Primary Cells
- ELISA KIT
- Natural Products
- Lab Equipments
- Humanized Mice for PDX Platform
- Rare Chemicals
- Custom Synthesis
- Antibacterial
- Antifungal
- Antioxidant
- Antiviral
- Molecular Glues
- SARS-CoV
![[Orn8]-Urotensin II acetate](https://img.aobious.com/img/p/5/4/5/9/2/54592-large_default.webp "[Orn8]-Urotensin II acetate")
![[Orn8]-Urotensin II acetate](https://img.aobious.com/img/p/5/4/5/9/2/54592.jpg "[Orn8]-Urotensin II acetate")
Quantity Discount Table - Order More To Get More Price Discount
| Quantity | mg | Unit Price ($/mg or $/Unit) | Final Price |
|---|---|---|---|
| 1 | 5 | $141.10 | Total: $705.50 |
| 1 | 10 | $119.52 | Total: $1,195.20 |
| 1 | 25 | $101.26 | Total: $2,531.50 |
| 1 | 50 | $86.32 | Total: $4,316.00 |
| 1 | 100 | $74.70 | Total: $7,470.00 |
Overview
[Orn8]-Urotensin II acetate is a Urotensin receptor ligand and a partial agonist at Urotensin receptors.
Chemical Properties
| Molecular Formula | C65H87N13O20S2 |
| Molecular Weight | 1434.59 |
| Solubility | DMSO |
| Purity | 98% by HPLC |
| SMILES Code | O=C([C@H]([C@@H](C)O)NC([C@@H](N)CCC(O)=O)=O)N(CCC1)[C@H]1C(N[C@H](CC(O)=O)C(N[C@H]2C(N[C@@H](CC3=CC=CC=C3)C(N[C@@H](CC4=CNC5=C4C=CC=C5)C(N[C@@H](C(N[C@@H](CC6=CC=C(O)C=C6)C(N[C@H](C(N[C@H](C(C)C)C(O)=O)=O)CSSC2)=O)=O)CCCN)=O)=O)=O)=O)=O.CC(O)=O |
Storage and Handling
0C Short Term, -20C Long Term
References
Vergura R, et al. Urotensin II stimulates plasma extravasation in mice via UT receptor activation. Naunyn Schmiedebergs Arch Pharmacol. 2004 Nov;370[5] 347-52.